Silk fibroin (SF) peptide has been traditionally used as a treatment for flatulence, spasms, and phlegm. In this study, we examined whether SF peptide enhanced the antiinflammatory effect of PEP-1-FK506 binding protein (PEP-1-FK506BP) through comparing the anti-inflammatory activities of SF peptide and/or PEP-1-FK506BP. In the presence or absence of SF peptide, transduction levels of PEP-1-FK506BP into HaCaT cells and mice skin and anti-inflammatory activities of PEP-1-FK506BP were identified by Western blot and histological analyses. SF peptide alone effectively reduced both mice ear edema and the elevated levels of cyclooxygenase-2, interleukin-6 and -1β, and tumor necrosis factor-α, showing similar anti-inflammatory effect to that of PEP-1-FK506BP. Furthermore, co-treatment with SF peptide and PEP-1-FK506BP exhibited more enhanced anti-inflammatory effects than the samples treated with SF peptides or PEP-1-FK506BP alone, suggesting the possibility that SF peptide and PEP-1-FK506BP might interact with each other. Moreover, the transduction data demonstrated that SF peptide did not affect the transduction of PEP-1-FK506BP into HaCaT cells and mice skin, indicating that the improvement of anti-inflammatory effect of PEP-1-FK506BP was not caused by enhanced transduction of PEP-1-FK506BP. Thus, these results suggest the possibility that co-treatment with SF peptide and PEP-1-FK506BP may be exploited as a useful therapy for various inflammationrelated diseases.
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Keywords: Inflammation, PEP-1-FK506BP, protein transduction, reactive oxygen species, silk fibroin peptide, TPA During various cellular processes, reactive oxygen species (ROS), such as hydroxyl radicals, superoxide anion, and hydrogen peroxide, are generated and, consequently, can cause lipid peroxidation, DNA damage, cell death, and various diseases, resulting in inflammation, cancer, Parkinson's disease, and ischemia [1, 5, 19] . Treatment with lipopolysaccharides (LPS) or 12-O-tetradecanoylphorbol-13-actate (TPA), known as inflammation inducers used in animal models [25, 30] , can activate macrophages and secrete pro-inflammatory mediators, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1beta (IL-1β), and tumor necrosis factor-alpha (TNF-α). In addition, nuclear factor-kappaB (NF-κB) and mitogen-activated protein kinase (MAPK) pathway are related to inflammatory responses [7, 8] .
FK506 binding proteins (FK506BPs) are members of an immunophilins family, which can bind immunosuppressive drugs such as rapamycin and FK506, used in prevention of graft rejection following organ transplantation [2, 11, 21] . In particular, FK506BP, a small peptide of 12 kDa, was first associated with rapamycin. The resultant FK506BP-rapamycin complex binds to and then disrupts the formation of activated mammalian target of rapamycin complex 1 (mTORC1), which can control protein synthesis, cell proliferation, and cell growth in response to nutrients and growth factors, leading to the suppression of protein synthesis and cell growth [4, 6, 16] . Furthermore, we previously reported that, through fusing FK506BP with a *Corresponding author Phone: +82-33-248-2112; Fax: +82-33-248-3201; E-mail: sychoi@hallym.ac.kr, nssur771@hallym.or.kr † These authors contributed equally to this work PEP-1 domain, PEP-1-FK506BP could be delivered to cell lines and tissues and exert anti-inflammatory activity, thereby suggesting that PEP-1-FK506BP may be used as a potential therapeutic drug for inflammatory diseases and especially atopic dermatitis [13, 14] .
Silk protein derived from silkworms (Bombyx mori) consists of fibroin and sericin. Although sericin, which naturally coats fibroin proteins, can induce allergic and inflammatory responses, fibroin protein, showing the resistance to temperature, moisture, and mechanical stresses, has been used for surgical suture after the removal of sericin. Moreover, many studies have reported that silk fibroin (SF) peptide can be a good candidate for tissue engineering scaffold applications [18] . In addition, various biological properties of silk fibroin proteins have been widely studied. Low molecular weight SF is shown to upregulate the osteoblastogenic gene expression, such as alkaline phosphatase, collagen type-I alpha-1, and TGFbeta1, in MG63 cells [12] . Fibroin peptide, when orally administered to hypertensive rats, proved to significantly decrease the blood pressure of hypertensive rats [10] . Hyun et al. [9] reported that fibroin peptide can improve diabetic hyperglycemia in 3T3-L1 adipocytes.
Therefore, the objective of this study was to examine whether SF peptides could exert in vivo anti-inflammatory activity, using reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis, and also whether cotreatment with SF peptide and PEP-1-FK506BP may be exploited as a potential therapy for various inflammatory diseases, compared with treatment with PEP-1-FK506BP or SF peptide alone.
MATERIALS AND METHODS

Materials and Cell Culture
Primary antibodies against COX-2 and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other chemicals and reagents were obtained from Sigma-Aldrich (MO, USA) unless otherwise stated. HaCaT human keratinocytes were grown in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal bovine serum and antibiotics (100 µg/ml streptomycin and 100 U/ml penicillin) and kept at 37 o C under a humidified atmosphere of 95% air and 5% CO 2 .
Preparation of SF Peptide
The preparation of low molecular weight SF peptide was conducted according to the Rural Development Administration (RDA) as previously described [12] . Silk cocoons were harvested from the RDA (Suwon, Korea). The sliced silk cocoons were degummed twice with Marseilles soap (0.5% of the weight of fiber) and sodium carbonate solution (0.3% of the weight of fiber) at 100 o C for 1 h, and then washed with distilled water to remove silk sericin. SF was digested by 6 M HCl for 5 h and stopped by the addition of NaOH. Removal of salt from SF peptide was performed using an electrodialysis system, after which SF powder was finally obtained using freeze-drying methods. The molecular mass of the SF peptide was approximately 3,000 Da.
Transductions of PEP-1-FK506BP and FK506BP into HaCaT Human Keratinocytes Cells PEP-1-FK506BP and FK506BP were purified as previously described [13, 14] . To assess the concentration dependence of PEP-1-FK506BP and FK506BP transduction in the absence or presence of SF peptide, cells were grown to confluence in wells of a 6-well plate, pretreated with or without SF peptide (0.3 µg/ml) for 1 h, and then exposed to various concentrations (0.5-3.0 µM) of each protein for an additional 1 h. To investigate the difference in the transduction of PEP-1-FK506BP (3.0 µM) in the presence of various concentrations (0.5-5.0 µg/ml) of SF peptide, cells were exposed to various concentrations of SF peptide for 1 h, prior to treatment with PEP-1-FK506BP (3.0 µM) for 1 h. Then, the cells were harvested and cell extracts were prepared for Western blot analysis.
Western Blot Analysis
Proteins in cell lysates and ear biopsy homogenates were resolved by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a nitrocellulose membrane. The membrane was blocked with 5% non-fat dry milk in PBS and incubated with a rabbit anti-histidine polyclonal antibody for detections of FK506BP and PEP-1-FK506BP or the primary antibodies against COX-2 and β-actin (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation with horseradish peroxidaseconjugated secondary antibody (dilution 1:10,000; Sigma-Aldrich, St. Louis, MO, USA). The membrane was visualized by enhanced chemiluminescence (ECL) according to the manufacturer's instructions (Amersham, Piscataway, NJ, USA). Band intensity was measured using a densitometer and analyzed using Image J software (NIH, Bethesda, MD, USA).
Animal Study
Male 6-8-week-old ICR mice were purchased from the Hallym University Experimental Animal Center. The animals were housed at a constant temperature (23 o C) and relative humidity (60%) with alternating 12 h cycles of light and dark. They were permitted access to food and water ad libitum. All experimental procedures involving animals and their care conformed to the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research and Quarantine Service of Korea and were approved by the Hallym Medical Center Institutional Animal Care and Use Committee.
In Vivo Transduction of PEP-1-FK506BP and FK506BP into Mice Ear To examine the effect of SF peptide on the transduction of PEP-1-FK506BP and FK506BP into mice tissues, SF peptide (3.0 µg/ear) was topically applied on the ear surface and then the same surface of mice ear was exposed to PEP-1-FK506BP or FK-506BP (3.0 µg/ear) 1 h later. Ear biopsy samples were immunostained using a rabbit anti-histidine polyclonal antibody (1:400) and biotinylated goat antirabbit secondary antibody (1:200). The sections were visualized with 3, 3'-diaminobenzidine and observed microscopically.
TPA-Induced Skin Inflammation Mouse Model
To induce skin inflammation, the right ear of each mouse (n = 5) was topically treated with TPA (1.0 µg) dissolved in 20 µl of acetone as
